Editing Gabapentin (section)

===Neuropathic pain===
Gabapentin is recommended as a first-line treatment for chronic neuropathic pain by various medical authorities.<ref name="NICE"/><ref name=Attal2010 /><ref name="pmid17372630">{{cite journal | vauthors = Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A | title = Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society | journal = Pain Research & Management | volume = 12 | issue = 1 | pages = 13–21 | date = 2007 | pmid = 17372630 | pmc = 2670721 | doi = 10.1155/2007/730785 | title-link = doi | doi-access = free }}</ref><ref name="pmid25575710">{{cite journal | vauthors = Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M | title = Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis | journal = The Lancet. Neurology | volume = 14 | issue = 2 | pages = 162–173 | date = February 2015 | pmid = 25575710 | pmc = 4493167 | doi = 10.1016/S1474-4422(14)70251-0 }}</ref> This is a general recommendation applicable to all neuropathic pain syndromes except for [[trigeminal neuralgia]], where it may be used as a second- or third-line agent.<ref name=Attal2010 /><ref name="pmid25575710"/>

Regarding the specific diagnoses, a systematic review has found evidence for gabapentin to provide pain relief for some people with [[postherpetic neuralgia]] and [[diabetic neuropathy]].<ref name=Wiffen2017>{{cite journal | vauthors = Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, Moore RA | title = Gabapentin for chronic neuropathic pain in adults | journal = The Cochrane Database of Systematic Reviews | volume = 6 | issue = 6 | pages = CD007938 | date = June 2017 | pmid = 28597471 | pmc = 6452908 | doi = 10.1002/14651858.CD007938.pub4 | hdl = 10044/1/52908 }}</ref> Gabapentin is approved for the former indication in the US.<ref name="Neurontin label" /> In addition to these two neuropathies, [[European Federation of Neurological Societies]] guideline notes gabapentin effectiveness for [[central pain]].<ref name=Attal2010 /> A combination of gabapentin with an [[opioid]] or [[nortriptyline]] may work better than either drug alone.<ref name=Attal2010 /><ref name="pmid25575710" />

Gabapentin shows substantial benefit (at least 50% pain relief or a patient global impression of change (PGIC) "very much improved") for neuropathic pain (postherpetic neuralgia or peripheral diabetic neuropathy) in 30–40% of subjects treated as compared to those treated with [[placebo]].<ref name=Wiffen2017/><!-- Not summarized in quite the same way in the cited source. -->

Evidence finds little or no benefit and significant risk in those with chronic [[low back pain]] or [[sciatica]].<ref>{{cite journal | vauthors = Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, Devereaux PJ, Bhandari M | title = Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials | journal = PLOS Medicine | volume = 14 | issue = 8 | pages = e1002369 | date = August 2017 | pmid = 28809936 | pmc = 5557428 | doi = 10.1371/journal.pmed.1002369 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, Maher CG, Lin CC | title = Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis | journal = CMAJ | volume = 190 | issue = 26 | pages = E786–E793 | date = July 2018 | pmid = 29970367 | pmc = 6028270 | doi = 10.1503/cmaj.171333 }}</ref> Gabapentin is not effective in [[HIV]]-associated [[Peripheral neuropathy|sensory neuropathy]]<ref>{{cite journal | vauthors = Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS | title = Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials | journal = PLOS ONE | volume = 5 | issue = 12 | pages = e14433 | date = December 2010 | pmid = 21203440 | pmc = 3010990 | doi = 10.1371/journal.pone.0014433 | title-link = doi | doi-access = free | bibcode = 2010PLoSO...514433P }}</ref> and neuropathic pain due to [[cancer]].<ref name="pmid29486015">{{cite journal | vauthors = Moore A, Derry S, Wiffen P | title = Gabapentin for Chronic Neuropathic Pain | journal = JAMA | volume = 319 | issue = 8 | pages = 818–819 | date = February 2018 | pmid = 29486015 | doi = 10.1001/jama.2017.21547 }}</ref>